Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 12/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FSHR | P23945 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13688205 | 0.84 | KCNQ2 (0.39) | KCNH2GSK3BDYRK1AKIF18AKCNQ3 | |
| SCHEMBL960582 | 0.82 | KCNH2 (0.49) | KCNH2KIF18ANPY1R | |
| SCHEMBL112418 | 0.79 | SCN9A (0.34) | KCNH2GSK3BDYRK1AKIF18AKCNQ3 | |
| SCHEMBL113691 | 0.79 | KIF18A (0.37) | KIF18AKCNQ3KCNQ2TSHRFSHR | |
| SCHEMBL503769 | 0.78 | KCNH2 (0.33) | KCNH2GSK3BDYRK1AKIF18AKCNQ3 | |
| SCHEMBL962171 | 0.78 | NPY1R (0.48) | KCNH2NPY1R | |
| SCHEMBL963106 | 0.76 | TSHR (0.38) | GSK3BDYRK1AKIF18AKCNQ3KCNQ2 | |
| SCHEMBL13012098 | 0.76 | SCN9A (0.35) | KIF18AKCNQ3KCNQ2TSHRFSHR | |
| SCHEMBL962961 | 0.76 | NPY1R (0.50) | KCNH2KIF18ANPY1R | |
| SCHEMBL13012095 | 0.75 | NOS3 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | KCNH2 1295/4885GSK3B 4546/4885DYRK1A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.